Trulieve Posts Profit on Strong Margins as Cannabis Rescheduling Unlocks New Opportunities

Event summary

  • Trulieve reported $287M in Q1 2026 revenue with a 59% gross margin and $2M in net income.
  • The company generated $100M in adjusted EBITDA, representing 35% of revenue.
  • Trulieve opened seven new dispensaries in Florida and expanded its rewards program to 1M members.
  • The Trump Administration reclassified medical marijuana to Schedule III, enabling Trulieve to file DEA registration applications for 206 retail locations.

The big picture

Trulieve's Q1 2026 results highlight the company's ability to generate strong cash flow and profitability in a highly regulated industry. The rescheduling of medical marijuana to Schedule III by the Trump Administration presents a significant strategic opportunity for Trulieve to expand its operations and explore new business models. The company's focus on operational efficiency and market positioning will be critical in maintaining its leadership position in the U.S. cannabis market.

What we're watching

Regulatory Tailwinds
How the rescheduling of medical marijuana to Schedule III will accelerate Trulieve's expansion into new markets and product categories.
Operational Efficiency
Whether Trulieve can sustain its 59% gross margin amid potential cost pressures from rapid expansion.
Market Positioning
The pace at which Trulieve can leverage its 240 retail dispensaries and 4M sq ft of cultivation capacity to dominate key cannabis markets.